ABT Overextended at $112.68: Trim to 50-60% Benchmark Weight on 1.3:1 Risk-Reward and 14.8% Extension
The convergence of two bearish analysts on tactical direction—supported by 1.3:1 asymmetric risk-reward, RSI 73.20, MACD divergence, and 14.8% price extension above 50 SMA—justifies Underweight over Hold. Valuation is elevated at TTM P/E 36.5x and PEG 2.24, with $6.06 normalized EPS recovery representing a high-dependency forecast. Prior Hold calls averaging +0.3% alpha demonstrate structural underperformance during rising-tape windows. Franchise quality (fortress balance sheet, 2.27% yield, $105.50 200 SMA support) prevents full exit but does not support holding full benchmark weight at current stretched technicals.
| Position | Action |
|---|---|
| Current benchmark weight position | Reduce to 50-60% of benchmark weight via 2-3 tranches over 1-2 weeks |
| Daily close below $105.50 on volume >7M | Trigger further trim toward Sell |
| Fed signals or hot CPI data accelerates downside timeline | Discretionary tightening of stop to $108 close |
ABT is at an inflection point warranting aggressive accumulation now, not a wait-and-see posture, given confirmed structural uptrend, multiple catalysts, and favorable macro tailwinds aligning simultaneously.
| Indicator | Value | Signal |
|---|---|---|
| 200 SMA | $105.98 | bullish |
| 50 SMA | $98.13 | bullish |
| 10 EMA | $109.74 | bullish |
| RSI (14) | 73.20 | bearish |
| MACD | 3.91 (signal 3.87, histogram 0.04) | neutral |
| Bollinger Middle Band (20 SMA) | $107.22 | bullish |
| Bollinger Upper Band | $113.97 | bearish |
| ATR (14) | $2.68 | neutral |
Support: 109.74 · 105.98 · 98.13 · 90.15 · 88.33 | Resistance: 113.97 · 114.81 · 122 · 128
ABT is in a confirmed short-term uptrend following a major bottom at $83.48 (May 8, 2026), with price now +6.3% above the 200 SMA and +14.8% above the 50 SMA. The rally is extended and showing early momentum fatigue: RSI at 73.20 is overbought, MACD histogram has flattened at 0.04 despite price making new highs (nascent bearish divergence), and price tagged but failed to close above the Bollinger Upper Band at $113.97. ATR has compressed from $3.15 to $2.68, supporting tighter stops. Immediate resistance is at $113.97–$114.81; key support tiers are the 10 EMA ($109.74) and 200 SMA ($105.98). The report recommends tactical bullish positioning with HOLD as the transaction proposal, favoring pullback entries to $109–$110 rather than chasing at current levels, with a stop below $105.98 to protect the long-term reclaim thesis.
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: $114 breakout on volume >10M with RSI re-accelerating above 65
Then: Re-engage/layer back into position
↩ rebuts: “Bear's 'complete recovery' framing”
EV: ~5–18% upside to prior range over 3–6 months · concedes: Quality is high but valuation is full — the bear correctly notes ABT trades near S&P 500 P/E multiples; DXCM's G7 15-Day rollout is a real competitive development worth monitoring
ABT is a quality franchise at full price, in a tightening macro, with stretched momentum and bearish technical divergence — the easy money has been made and risk-reward skews negative.
· concedes: A daily close above $114.00 on volume >10M would invalidate the technical bearishness; ABT is a quality franchise with a strong dividend history; The MACD histogram hasn't crossed zero yet because the move is young — could resolve bullishly
→ vs neutral: Cognitive dissonance: cannot acknowledge RSI at 73.20, MACD flatlining, price failing to close above upper Bollinger Band, and declining volume on successive pushes higher, then recommend HOLD
→ vs conservative: Would agree with sell recommendation
→ vs neutral: Fortress balance sheet at wrong price is still a bad trade; defensive characteristics don't protect from valuation compression
→ vs aggressive: World affairs analyst recommending BUY is late to the defensive rotation trade which already played out from $83.48 to $112.68
→ vs aggressive: Google Lingo partnership is low-revenue, high-narrative story that won't move the needle on revenue 12 months later
→ vs neutral: If fundamentals are 'full' and technicals are breaking down, the bullish thesis is built on hope, not analysis
Market Cap
$194.98 B
Current Price
~$112.71
52-Week High
$137.49
52-Week Low
$81.97
50-Day Moving Average
$98.02
200-Day Moving Average
$107.28
Beta
0.581
P/E (TTM)
36.47
Forward P/E
18.58
PEG Ratio
2.24
P/B
3.81
EPS (TTM)
$3.09
Forward EPS
$6.06
Revenue FY2025
$44.33 B
Revenue FY2024
$41.95 B
Revenue FY2023
$40.11 B
Revenue FY2022
$43.65 B
Revenue FY2021
$43.65 B
Gross Profit FY2025
$25.01 B
Gross Margin FY2025
56.4%
Operating Income FY2025
$8.05 B
Operating Margin FY2025
18.2%
Net Income FY2025
$6.52 B
Net Margin FY2025
11.6% (GAAP) / 14.7% (TTM underlying)
EBITDA FY2025
$12.08 B
EPS FY2025
$3.72
EPS FY2024
$7.64
EPS FY2023
$3.26
EPS FY2022
$3.91
EPS FY2021
$3.99
Total Assets FY2025
$86.71 B
Total Equity FY2025
$52.13 B
Total Debt FY2025
$13.86 B
Cash & Equivalents FY2025
$8.52 B
Net Debt FY2025
$4.41 B
Goodwill FY2025
$24.04 B
Other Intangibles FY2025
$5.53 B
Net Tangible Assets FY2025
$22.57 B
Debt-to-Equity
0.27
Net Debt / EBITDA
0.36x
Current Ratio
1.38
Working Capital FY2025
$9.5 B
Operating Cash Flow FY2025
$9.57 B
CapEx FY2025
$2.17 B
Free Cash Flow FY2025
$7.40 B
FCF Yield
~3.8%
Dividends Paid FY2025
$4.12 B
Buybacks FY2025
$0.89 B
SG&A FY2025
$12.33 B
R&D FY2025
$2.94 B
ROE
10.6%
ROA
5.3%
Strengths
Concerns
Abbott Laboratories (ABT) is a diversified healthcare powerhouse with 2025 revenue of $44.33B and EBITDA of $12.08B, recovering from a COVID-driven revenue trough in 2023. The company generates strong free cash flow ($7.40B in 2025, 3.8% FCF yield) with an extremely conservative balance sheet (0.36x Net Debt/EBITDA) and maintains stable gross margins of ~56%. The stock trades at a forward P/E of 18.6x with a PEG of 2.24, reflecting a premium for its defensive characteristics (beta 0.581) and quality franchise positioning anchored by the FreeStyle Libre CGM platform. The recommendation is HOLD, with accumulation opportunities on weakness below the 50-day MA (~$98).
Macro: Risk-off and yield-driven environment as of week of Aug 11–18, 2026. The 30-year Treasury yield touched a 19-year high during the week, with bonds 'slamming' equities and tech leading US indexes lower (Nasdaq slid for third consecutive day). Traders rotating into Energy as defensive hedge amid escalating Middle East conflict fears and crude oil gains. Fed rate expectations have sharply shifted: Polymarket pricing shows 85% probability of no Fed rate cuts in 2026, September FOMC meeting at 70% probability of no change (vs +12pp prior week), 28% probability of 25-bps hike (–11pp), and only 1% probability of 25-bps cut. US recession probability by end-2026 remains low at 8% (–1pp week-over-week), with soft-landing narrative intact. The environment is mildly negative for valuation multiples but favors defensives and dividend payers; Abbott's Medical Devices franchise is relatively rate-insensitive (hospital capex and procedure volumes), making ABT a relative beneficiary of tactical rotation from high-multiple tech/AI names.